{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1360011144328060928.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1002/cncr.24400"}},{"identifier":{"@type":"URI","@value":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fcncr.24400"}},{"identifier":{"@type":"URI","@value":"https://acsjournals.onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.24400"}}],"dc:title":[{"@value":"Cervical cancer histology and tumor differentiation affect <sup>18</sup>F‐fluorodeoxyglucose uptake"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:title>Abstract</jats:title><jats:sec><jats:title>BACKGROUND:</jats:title><jats:p>This study aimed to evaluate the variation in cervical cancer glucose metabolism for different tumor histologies and levels of differentiation, as measured by the uptake of <jats:sup>18</jats:sup>F‐fluorodeoxyglucose (FDG) by positron emission tomography (PET).</jats:p></jats:sec><jats:sec><jats:title>METHODS:</jats:title><jats:p>The study population consisted of 240 patients with International Federation of Gynecology and Obstetrics stages Ib1 through IVb cervical cancer, who underwent a pretreatment FDG‐PET. Tumor histology included 221 squamous cell (SC), 4 adenosquamous (AS), and 15 adenocarcinoma (AC) tumors. There were 14 well, 145 moderately, and 81 poorly differentiated tumors. The stage distribution was as follows: 70 stage I tumors (9 AC, 2 AS, and 59 SC), 102 stage II tumors (3 AC, 1 AS, and 98 SC), 64 stage III tumors (3 AC, 1 AS, and 60 SC), and 4 stage IV tumors (4 SC). From the FDG‐PET, maximal standardized uptake value (SUV<jats:sub>max</jats:sub>) was determined. The variation in SUV<jats:sub>max</jats:sub> was analyzed for differences based on tumor histology and differentiation.</jats:p></jats:sec><jats:sec><jats:title>RESULTS:</jats:title><jats:p>For all patients, the mean SUV<jats:sub>max</jats:sub> was 11.62 (range, 2.50‐50.39). The mean SUV<jats:sub>max</jats:sub> by histology was as follows: SC, 11.91 (range, 2.50‐50.39); AS, 8.85 (range, 6.53‐11.26); and AC, 8.05 (range, 2.83‐13.92). Squamous versus nonsquamous tumors demonstrated a significant difference in SUV<jats:sub>max</jats:sub> (<jats:italic>P</jats:italic> = .0153). SUV<jats:sub>max</jats:sub> and tumor volume were not found to be correlated (<jats:italic>R</jats:italic><jats:sup>2</jats:sup> = 0.013). The mean SUV<jats:sub>max</jats:sub> was 8.58 for well‐differentiated, 11.56 for moderately differentiated, and 12.23 for poorly differentiated tumors. The mean SUV<jats:sub>max</jats:sub> was significantly different for well‒differentiated versus poorly differentiated cervical tumors (<jats:italic>P</jats:italic> = .0474).</jats:p></jats:sec><jats:sec><jats:title>CONCLUSIONS:</jats:title><jats:p>Cervical tumor FDG uptake varied by histology and differentiation. SC tumors demonstrated a significantly higher SUV<jats:sub>max</jats:sub> compared with nonsquamous cell tumors, and poorly differentiated tumors also had a higher SUV<jats:sub>max</jats:sub>. Cancer 2009. © 2009 American Cancer Society.</jats:p></jats:sec>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380011144328060928","@type":"Researcher","foaf:name":[{"@value":"Elizabeth A. Kidd"}]},{"@id":"https://cir.nii.ac.jp/crid/1380011144328061056","@type":"Researcher","foaf:name":[{"@value":"Christopher R. Spencer"}]},{"@id":"https://cir.nii.ac.jp/crid/1380011144328061058","@type":"Researcher","foaf:name":[{"@value":"Phyllis C. Huettner"}]},{"@id":"https://cir.nii.ac.jp/crid/1380011144328061060","@type":"Researcher","foaf:name":[{"@value":"Barry A. Siegel"}]},{"@id":"https://cir.nii.ac.jp/crid/1380011144328060929","@type":"Researcher","foaf:name":[{"@value":"Farrokh Dehdashti"}]},{"@id":"https://cir.nii.ac.jp/crid/1380011144328061059","@type":"Researcher","foaf:name":[{"@value":"Janet S. Rader"}]},{"@id":"https://cir.nii.ac.jp/crid/1380011144328061057","@type":"Researcher","foaf:name":[{"@value":"Perry W. Grigsby"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"0008543X"},{"@type":"EISSN","@value":"10970142"},{"@type":"PISSN","@value":"http://id.crossref.org/issn/0008543X"}],"prism:publicationName":[{"@value":"Cancer"}],"dc:publisher":[{"@value":"Wiley"}],"prism:publicationDate":"2009-05-26","prism:volume":"115","prism:number":"15","prism:startingPage":"3548","prism:endingPage":"3554"},"reviewed":"false","dc:rights":["http://onlinelibrary.wiley.com/termsAndConditions#vor"],"url":[{"@id":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fcncr.24400"},{"@id":"https://acsjournals.onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.24400"}],"createdAt":"2009-05-26","modifiedAt":"2025-10-12","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360283692557837440","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"The efficacy of preoperative positron emission tomography-computed tomography (PET-CT) for detection of lymph node metastasis in cervical and endometrial cancer: clinical and pathological factors influencing it"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285709887392384","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Role of PET/CT in Gynecological Tumors Based on the Revised FIGO Staging Classification"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1002/cncr.24400"},{"@type":"CROSSREF","@value":"10.1093/jjco/hyu161_references_DOI_TYYWIBzVVVGLsEFHvnvRzj6bxbS"},{"@type":"CROSSREF","@value":"10.1097/rlu.0b013e31821c9a9a_references_DOI_TYYWIBzVVVGLsEFHvnvRzj6bxbS"}]}